TheraRadar
← Back
Data updated: Nov 8, 2026

Amgen

AMGN Biotech
OncologyImmunologyMetabolic Execution: Good

Pioneer biotechnology company with strength in oncology and inflammation. Known for biologics innovation including Enbrel, Repatha, and biosimilar portfolio.

$33.4B
Revenue (2024)
$155.0B
Market Cap
-
Trials
3
New Drugs (2yr)
Modality:
3 Small Molecules 14 Biologics

FDA Novel Drug Designations

(2018-2024)
4 Novel 4 First-in-Class 2 Orphan 2 Breakthrough 2 Accelerated 2 Priority Review 1 Fast Track
See 4 novel approvals →
2024 IMDELLTRA (TARLATAMAB-DLLE) First-in-Class · Orphan · Breakthrough · Priority Review · Accelerated
2021 LUMAKRAS (SOTORASIB) First-in-Class · Orphan · Breakthrough · Priority Review · Accelerated · Fast Track
2019 EVENITY (ROMOSOZUMAB-AQQG) First-in-Class
2018 AIMOVIG (ERENUMAB-AOOE) First-in-Class

Amgen at a Glance

  • Leading 15 drug targets across portfolio
  • Fast trial execution (27 months median completion)

Amgen's Recent FDA Approvals

Amgen secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

PAVBLU BLA
2026-10-22
aflibercept-ayyh
Neovascular Age-Related Macular Degeneration
OTEZLA NDA
2025-08-29
apremilast
Active psoriatic arthritis
OTEZLA NDA
2025-08-29
apremilast
Active psoriatic arthritis

Amgen's Therapeutic Areas

Amgen's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Immunology, across 14 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 42%
10 drugs Phase 3: 50 Phase 2: 35 Phase 1: 113
Immunology 26%
7 drugs Phase 3: 38 Phase 2: 24 Phase 1: 34
Metabolic 17%
0 drugs Phase 3: 30 Phase 2: 12 Phase 1: 31
Cardiovascular 8%
1 drugs Phase 3: 14 Phase 2: 6 Phase 1: 5
Gastroenterology 7%
5 drugs Phase 3: 4 Phase 2: 6 Phase 1: 13

Amgen Pipeline Snapshot

Amgen has 415 active clinical programs from ClinicalTrials.gov — 136 Phase 3, 83 Phase 2 and 196 Phase 1.

136
Phase 3
83
Phase 2
196
Phase 1

Phase 3 Readout Calendar Pro

8 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q4 2026
ABP 234
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Estimated · aging NCT06430866
Q1 2027
Ocrelizumab (US)
Relapsing-remitting Multiple Sclerosis (RRMS)
Estimated · aging NCT06700343
Q1 2027
Maridebart cafraglutide
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Estimated · aging NCT06858878
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • REPATHA leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Oncology pipeline focus
  • • 8 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 148/214 completed
  • • Speed: 27 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges